Purpose: Malignant gliomas are the most common tumors in the central nervous system with a poor prognosis. Recently, CD4 cytotoxic T cells (CTLs) are being increasingly recognized as possessing antitumor capacity. However, their presence, activity and regulation in glioma have not been investigated in detail.

Methods: To examine this, 72 grade II and grade III Han Chinese glioma patients and 30 Han Chinese healthy controls were investigated.

Results: We found that compared to healthy controls, glioma patients had significantly upregulated frequencies of circulating CD4 CTLs, identified by the expression of granzyme A (GzmA), granzyme B (GzmB) and/or perforin. The stimulated CD4 CTLs in grade II and grade III glioma patients also had less proliferative ability than those in healthy controls, a feature of suppression that progressed with tumor grade. The frequencies of GzmB-expressing circulating CD4 CTLs were directly associated with prognosis. We hypothesized that the programed death 1 (PD-1)/PD-ligand 1 (L1) interaction possibly contributed to the suppression of CD4 CTLs in grade II and grade III glioma, since an upregulation of PD-1 was observed on CD4 CTLs in glioma compared to those in the healthy individuals. Blockade of the PD-1/PD-L1 interaction with neutralizing antibodies significantly increased the proliferation and granzyme or perforin production by CD4 CTLs in grade II and grade III glioma patients.

Conclusions: These data suggest that the CD4 CTLs in grade II and grade III glioma patients contribute to antitumor immunity and could be suppressed by PD-1 signal transduction.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00207454.2016.1180597DOI Listing

Publication Analysis

Top Keywords

cd4 ctls
28
grade grade
24
grade iii
24
iii glioma
20
glioma patients
16
ctls grade
16
grade
13
han chinese
12
healthy controls
12
glioma
9

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!